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Background: Fluralaner (Bravecto™) is a novel systemic insecticide and acaricide that provides long persistent
antiparasitic activity following a single administration at the minimum dose of 25 mg/kg body weight.
Methods: Three negative controlled, randomized studies were conducted in dogs to evaluate the start to kill (1
study) and the speed of flea kill (2 studies) of fluralaner. All dogs were infested prior to treatment with unfed adult
C. felis fleas. Dogs in the treated groups were administered once orally with fluralaner at a minimum dose of
25 mg/kg body weight, while dogs in the control groups were not treated. Separate control and treatment groups
were paired at each time point of flea assessment. Flea counts were performed by combing dogs at either 0.5, 1, 2,
or 4 hours after fluralaner treatment to measure the start to kill. To evaluate the speed of flea kill over 12 weeks, flea
counts were performed by combing dogs at either 4, 8, 12, or 24 hours after fluralaner treatment and then at 4, 8,
12, or 24 hours after each flea re-infestations performed at 4, 8, and 12 weeks following treatment.
Results: In the start to kill study, the fluralaner activity against fleas started already at 1 hour post-treatment (8% numerical
efficacy). At 2 and 4 hours post-treatment, the flea reduction was significant with 36.7% and 88% efficacy, respectively.
In the speed of kill studies, the efficacy against fleas after fluralaner treatment was 80.5% at 4 hours and remained≥ 99.4%
at 8, 12 and 24 hours. After flea re-infestations in weeks 4, 8 and 12, the efficacy at 4 hours was 96.8, 91.4, and 33.5%,
respectively. Efficacy at 8, 12 and 24 hours after flea re-infestations was 98.0-100% for the 12 weeks of the study.
Except for 4 hours after the 12-week flea re-infestation, flea reduction was significant for all time points after flea
re-infestation.
Conclusions: Single oral fluralaner administration rapidly eliminates existing flea infestations and provides
excellent protection against fleas over 12 weeks following treatment.
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The cat flea, Ctenocephalides felis, is the main flea spe-
cies infesting dogs and cats [1] and the most important
ectoparasite for dogs in many parts of the world [2]. A
persistent flea infestation without treatment can provoke
intense pruritus, self-inflicted trauma and even, in case
of massive infestation, anemia [2]. In some dogs, flea ex-
posure leads to the more serious condition of flea allergy
dermatitis (FAD), a result of hypersensitivity to flea* Correspondence: janina.taenzler@msd.de
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unless otherwise stated.saliva components [1]. Once sensitization has occurred,
relapse of lesions can be initiated by just a small number
of flea bites. Clinical signs are usually transient, but
chronic skin changes might occur, like alopecia, crusts,
hyperpigmentation and lichenification, if the flea infest-
ation is not eliminated [3]. Dogs are affected by the adult
fleas only. Other flea life-cycle stages contaminate their
environment, where flea development from egg via lar-
vae and pupae to newly emerged adult fleas takes place.
Elimination of adult fleas before they start laying eggs is
essential for successful flea control [4]. Approximately
24 hours are needed between the flea’s first blood meall. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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effectively kill all adult fleas within this time frame.
The active ingredient of Bravecto™, fluralaner, is a
member of the isoxazoline class, a novel class of antipar-
asitic drugs that inhibits γ-aminobutyric acid (GABA)-
and glutamate-gated chloride channels with significant
selectivity for insect neurons over mammalian neurons
[5,6]. Fluralaner formulated as a flavoured chewable tab-
let is commercially available for immediate and persist-
ent killing of ticks and fleas on dogs over 12 weeks,
eliciting its primary action through feeding activity [7]. In
a field trial, a single dose of fluralaner provided 12 weeks
activity against fleas in dogs [8], and it was shown to be
safe and well tolerated [8,9].
The aim of the current studies was to determine a)
how fast fluralaner starts to kill fleas (within 0.5-4 hours
post-treatment) and b) the speed of flea kill within the




Three blinded, randomized, negative controlled studies
were performed, one start to kill study in South Africa
and two speed of kill studies in Germany. The start to
kill study was conducted in accordance with Good Clin-
ical Practice (VICH guideline GL9, Good Clinical Prac-
tice (EMA, 2000)), in compliance with the South African
National Standard “SANS 10386:2008: The care and use of
animals for scientific purposes” and ethical approval was
obtained by the ClinVet Animal Ethics Committee (CAEC)
before the study start. The 2 speed of kill studies were con-
ducted in accordance with the OECD Principles of Good
Laboratory Practice (GLP) and the GLP Principles of the
German “Chemikaliengesetz” (Chemicals Act), in compli-
ance with the German animal welfare regulations and eth-
ical approval was obtained before the start of the study.
For each flea assessment time point in each of the
three studies, 6 treated dogs and 6 control dogs were in-
cluded, thus in total 96 dogs (52 male and 44 female).
All dogs included were over 6 months of age, weighed
between 8.9 and 18.8 kg, and were mixed or pure bred
(Beagles). Each dog was in good health, had not been
treated with any parasite control product within 3 months
prior to a 7 day acclimatization period, and was uniquely
identified by a microchip number. In the start to kill study
and the speed of kill studies, laboratory bred flea strains,
both originating from Germany and collected from the
field less than 10 years prior to the studies, were used.
Within the acclimatization period, the flea susceptibil-
ity of each dog was confirmed by a flea infestation with
100 (± 4) fleas (start to kill) or 80 fleas (speed of kill),
followed by flea removal and count 24 (± 2) hours later.
All dogs included in the study harboured more than 50%of the number of originally infested fleas. Ranking of the
dogs was performed within gender (start to kill study) or
without gender separation (speed of kill studies) by de-
scending flea counts and dogs were randomly allocated to
study groups using a computer generated randomization
list. In the start to kill study, dogs were housed individu-
ally. In the speed of kill studies, dogs were group-housed
within their corresponding study group during periods
without flea infestation. On days when dogs carried fleas,
all dogs were individually housed.
Treatment
One or 2 days before treatment, all dogs were infested
with either 100 (± 4) (start to kill study) or 80 (speed of
kill studies) unfed adult C. felis fleas. On the day of treat-
ment (day 0), each dog received half of its daily food ra-
tio approximately 20 minutes before treatment and the
balance directly after treatment. Dogs in the treatment
groups were treated orally with fluralaner chewable tab-
lets (Bravecto™), based on the dog’s individual body
weight, to achieve a minimum dose of 25 mg fluralaner/
kg body weight. The chewable tablet was administered
by placement in the back of the oral cavity over the
tongue to initiate swallowing. Each treated dog was con-
tinuously observed for 1 hour after administration to
monitor for vomit or tablet/s spit out, which did not occur
in any of the 3 studies. Control group dogs remained un-
treated. General health observations were performed daily
throughout the complete study period in all 3 studies.
Flea infestations and assessments
In the start to kill study, all dogs were infested with 100
(± 4) fleas 1 day before treatment. Flea counts were per-
formed with one pair of treatment plus control group at
either 0.5 (± 5 min), 1 (± 15 min), 2 (± 15 min), or 4 (±
15 min) hours after fluralaner treatment. In the two
speed of kill studies, dogs were infested with 80 fleas on
days −2, 28 (4 weeks), 56 (8 weeks) and 84 (12 weeks).
Flea counts were performed with one pair of treatment
plus control group at either 4 and 8 (± 0.75) hours in
one study or at 12 and 24 (± 1.5) hours in the other
study after fluralaner treatment (week 0) or each flea re-
infestation (weeks 4, 8, and 12). Each dog was combed
to remove and count live adult fleas. Personnel conducting
comb counts were blinded with regard to study group.
Efficacy evaluation
The individual dog was the experimental unit in all statis-
tical calculations. Data from each flea count time point were
analysed separately. Significant differences were assessed be-
tween the log-counts of adult live fleas in each treated group
at each assessment time point in comparison to the log-
counts of the respective untreated control group. Study
groups were compared using a linear mixed model including
Table 1 Start to kill study: mean flea counts, flea count range and percentage efficacy 0.5, 1, 2, and 4 hours after a
single oral administration of fluralaner to dogs
Time post treatment 0.5 hour 1 hour 2 hours 4 hours
Study Group Fluralaner Control Fluralaner Control Fluralaner Control Fluralaner Control
Meana flea counts (n) 78.71 73.96 78.14 84.89 48.70 76.97 7.38 61.57
Count range (n) 74-86 65-89 47-96 64-97 33-69 61-99 0-80 30-80
Efficacy (%) 0.0% 8.0% 36.7% b 88.0% b
aGeometric mean.
bLog-counts of live fleas from the treated group were significantly different (p ≤ 0.05) from log-counts of the respective untreated control group.
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The two-sided level of significance was declared when
P ≤ 0.05 (SAS Institute Inc., Cary, NC, USA, release 9.2).
Efficacy was calculated using geometric means with
Abbott’s formula:
Efficacy (%) = 100 x (MC - MT)/MC, where MC was the
mean number of total adult live fleas on untreated dogs
and MT the mean number of total adult live fleas on
treated dogs. In case of zero counts, the geometric mean









No adverse event considered to be related to oral flurala-
ner treatment was observed in any dog.
In the start to kill study (Table 1), the fluralaner activity
against fleas had started already at 1 hour post treatment
(8% numerical efficacy). Significant flea reduction was ob-
served at 2 and 4 hours (36.7% and 88% efficacy). One dogTable 2 Speed of kill studies: mean flea counts, flea count ran
oral administration of fluralaner to dogs
Assessment time pointsa 4 hours 8 hou
Study Group Fluralaner Control Flurala
Week 0 Meanb flea counts (n) 4.14 21.21 0.30
Count range (n) 0-21 1-71 0-4
Efficacy (%) 80.5%c 99.4%c
Week 4 Meanb flea counts (n) 2.38 74.78 0.0
Count range (n) 0-13 69-80 0
Efficacy (%) 96.8%c 100%c
Week 8 Meanb flea counts (n) 5.71 66.61 0.0
Count range (n) 0-43 60-77 0
Efficacy (%) 91.4%c 100%c
Week 12 Meanb flea counts (n) 45.91 69.02 1.49
Count range (n) 15-75 64-75 0-14
Efficacy (%) 33.5% 98.0%c
aAssessment for fleas xy hours after treatment or re-infestation following treatment
bGeometric mean.
cLog-counts of live fleas from the treated group were significantly different (p ≤ 0.0without any fleas and three dogs with ≤ 6 fleas were found
4 hours after treatment.
In the speed of kill studies (Table 2), the efficacy against
fleas after fluralaner treatment was 80.5% at 4 hours and
remained ≥ 99.4% at 8, 12 and 24 hours.
After flea re-infestations in weeks 4, 8 and 12 the effi-
cacy at 4 hours was 96.8, 91.4, and 33.5%, respectively.
Efficacy at 8, 12 and 24 hours after flea re-infestations
was 98.0-100% for the 12 weeks of the study. Only a few
or no fleas were observed on the dogs at these time
points. Except for 4 hours after the 12-week flea re-
infestation, flea reduction was significant for all time
points after treatment and re-infestation.
Discussion
Fluralaner (Bravecto™) is the first orally administered
ectoparasiticide to demonstrate an efficacy against fleas
over 12 weeks [7]. In the start to kill study, the results
show that orally administered fluralaner starts to kill present
fleas on the dog already 1 hour after treatment. At 4 hours
after treatment 88%, and at 8 hours after treatment 99.4% of
the fleas were killed. This pronounced efficacy at 8 hoursge and percentage efficacy over 12 weeks after a single
rs 12 hours 24 hours
ner Control Fluralaner Control Fluralaner Control
49.93 0.0 73.59 0.0 13.85
6-80 0 58-79 0 0-75
100%c 100%c
77.79 0.0 73.53 0.0 69.35
73-80 0 66-80 0 61-75
100%c 100%c
75.01 0.12 69.56 0.0 71.48
62-80 0-1 59-80 0 65-79
99.8%c 100%c
74.24 1.02 76.44 0.0 73.25
67-77 0-16 72-80 0 68-78
98.7%c 100%c
.
5) from log-counts of the respective untreated control group.
Taenzler et al. Parasites & Vectors 2014, 7:567 Page 4 of 4
http://www.parasitesandvectors.com/content/7/1/567post treatment was maintained for the full 12-week post
treatment period. This result is consistent with the
close to 100% efficacy observed at multiple time points
in a European field trial [8]. In that field trial, in a
fipronil-treated group the efficacy was lower at all time
points and required repeated monthly treatment to
reach an efficacy comparable to the one of fluralaner
after one administration. The pronounced flea efficacy
of fluralaner at 8 hours for a period of at least 12-
weeks post treatment contributes to the control of the
flea population in the environment by the gradual
elimination of flea stages. Female fleas start to lay eggs
within 24–48 hours after the initiation of the blood
meal, which is necessary for egg production and mat-
uration in fleas [10]. By killing all newly emerged adult
fleas before they start laying eggs over the extended
period of time of 12 weeks, the flea life cycle will be
disrupted, i.e. larvae, pupae and new adults will be
eradicated from the dog’s environment. The long last-
ing flea efficacy is strengthened by providing an add-
itional effect on flea reproduction, because fluralaner
directly reduces the pupal development and hence emer-
gence of new adult fleas [11]. Therefore, treatment with
fluralaner not only has an effect on the existing flea popula-
tion on the dog, it also contributes to the disruption of the
flea life cycle and thus to the extinction of flea burden in an
infested environment. Due to the quick onset of activity of
fluralaner, fewer fleas are able to bite, which supports the
treatment of FAD [8], even to an extent that no further
concomitant medication is required [unpublished observa-
tions]. A common factor for insufficient ectoparasite con-
trol in dogs is poor owner compliance with required
monthly re-treatment protocols for existing ectoparasite-
therapeutic options [12,13]. Poor owner compliance
may also encourage resistance in the flea population by
selecting for insecticide-tolerant individuals [13]. A long
re-treatment interval and greater owner compliance could
reduce the potential for resistance development. There-
fore, an active ingredient with a long re-treatment interval,
such as fluralaner, leads to better flea control.
Conclusions
A single oral administration of fluralaner to dogs, formu-
lated as chewable tablet (Bravecto™), leads to an onset of flea
killing activity starting at 1 hour and a flea efficacy 98-100%
at 8 hours after treatment or following re-infestation
throughout a 12-week post-treatment period. Flurala-
ner effectively kills fleas within a few hours after host
infestation, thus contributing to the disruption of the
flea life cycle, leading to a depletion of the environmental
flea population. This also supports the treatment of FAD.
The long re-treatment interval of fluralaner (Bravecto™)
offers more convenience over monthly flea-control treat-
ments with a potential compliance advantage.Competing interests
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